Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants


Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Stimulants01:29

Stimulants

Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Primary synovial sarcoma of the vulva: report of a case].

Zhonghua bing li xue za zhi = Chinese journal of pathology·2025
Same author

[Progression and application of circulating tumor DNA in lymphoma].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2024
Same author

[Mucoepidermoid carcinoma of the stomach: report of two cases].

Zhonghua bing li xue za zhi = Chinese journal of pathology·2024
Same author

High-'n'-dry? A comparison of cannabis and alcohol use in drivers presenting to hospital after a vehicular collision.

Addiction (Abingdon, England)·2023
Same author

Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Treatment of metastatic placental site trophoblastic tumor with surgery, chemotherapy, immunotherapy and coil embolization of multiple pulmonary arteriovenous fistulate.

Gynecologic oncology reports·2021
Same journal

Burkitt`s Lymphoma Presenting as Ileocolic Intussusception in a 8 year old boy.

Kathmandu University medical journal (KUMJ)·2026
Same journal

Negative Pressure Pulmonary Edema Following Septorhinoplasty.

Kathmandu University medical journal (KUMJ)·2026
Same journal

Corneal Deposits in a Jeweler: A case of ocular argyrosis.

Kathmandu University medical journal (KUMJ)·2026
Same journal

All on Four Implant Supported Denture -A zippy solution for complete edentulism.

Kathmandu University medical journal (KUMJ)·2026
Same journal

Eye Care Professionals' Knowledge, Attitude and Practice (KAP) on Myopia Management Approach: A Global Review.

Kathmandu University medical journal (KUMJ)·2026
Same journal

Breastfeeding Self-efficacy and Postnatal Depressive Symptoms: A Cross-sectional Study among Postnatal Women.

Kathmandu University medical journal (KUMJ)·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition
06:12

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition

Published on: March 3, 2023

Varenicline: for smoking cessation.

J Rao1, P K Shankar

  • 1Department of Pharmacology, Melaka Manipal Medical College, Manipal, India.

Kathmandu University Medical Journal (KUMJ)
|January 15, 2010
PubMed
Summary
This summary is machine-generated.

Varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, effectively aids smoking cessation by reducing cravings and relapse. It shows superior efficacy compared to other treatments for achieving long-term abstinence.

More Related Videos

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
08:47

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration

Published on: February 10, 2012

Related Experiment Videos

Last Updated: Jun 17, 2026

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition
06:12

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition

Published on: March 3, 2023

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
08:47

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration

Published on: February 10, 2012

Area of Science:

  • Pharmacology
  • Addiction Medicine
  • Neuroscience

Background:

  • Smoking cessation treatments have suboptimal abstinence rates.
  • Varenicline is a novel pharmacological agent for smoking cessation.
  • Nicotine replacement therapy and Bupropion sustained-release are existing treatments.

Purpose of the Study:

  • To review the mechanism of action of Varenicline.
  • To evaluate the efficacy of Varenicline for smoking cessation.
  • To assess the safety profile of Varenicline.

Main Methods:

  • Review of clinical trials and scientific literature.
  • Analysis of Varenicline's pharmacological properties as an alpha4beta2 nicotinic acetylcholine receptor (nAChR) partial agonist.
  • Comparison of Varenicline's efficacy and safety against Bupropion sustained-release (SR) and nicotine replacement therapy.

Main Results:

  • Varenicline attenuates nicotine craving and withdrawal symptoms.
  • It reduces the rewarding effects of nicotine in individuals who lapse.
  • Clinical trials demonstrate Varenicline's superior efficacy over Bupropion-SR in achieving smoking abstinence and delaying relapse.

Conclusions:

  • Varenicline represents a significant advancement in smoking cessation pharmacotherapy.
  • Its unique mechanism of action offers improved outcomes compared to existing therapies.
  • Varenicline is a safe and effective option for individuals seeking to quit smoking.